PL377939A1 - Kompozycja, zawierająca kombinację inhibitora aromatazy, progestagenu i estrogenu, oraz jej zastosowanie do leczenia endometriozy - Google Patents

Kompozycja, zawierająca kombinację inhibitora aromatazy, progestagenu i estrogenu, oraz jej zastosowanie do leczenia endometriozy

Info

Publication number
PL377939A1
PL377939A1 PL377939A PL37793904A PL377939A1 PL 377939 A1 PL377939 A1 PL 377939A1 PL 377939 A PL377939 A PL 377939A PL 37793904 A PL37793904 A PL 37793904A PL 377939 A1 PL377939 A1 PL 377939A1
Authority
PL
Poland
Prior art keywords
compositon
oestrogen
progestin
endometriosis
treatment
Prior art date
Application number
PL377939A
Other languages
English (en)
Other versions
PL214680B1 (pl
Inventor
Stephen Rubin
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of PL377939A1 publication Critical patent/PL377939A1/pl
Publication of PL214680B1 publication Critical patent/PL214680B1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL377939A 2003-02-05 2004-02-03 Zastosowanie kombinacji anastrozolu, lewonorgestrelu i etynyloestradiolu do wytwarzania leku do leczenia endometriozy PL214680B1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0302572.3A GB0302572D0 (en) 2003-02-05 2003-02-05 Method of treatment

Publications (2)

Publication Number Publication Date
PL377939A1 true PL377939A1 (pl) 2006-02-20
PL214680B1 PL214680B1 (pl) 2013-09-30

Family

ID=9952433

Family Applications (1)

Application Number Title Priority Date Filing Date
PL377939A PL214680B1 (pl) 2003-02-05 2004-02-03 Zastosowanie kombinacji anastrozolu, lewonorgestrelu i etynyloestradiolu do wytwarzania leku do leczenia endometriozy

Country Status (29)

Country Link
US (2) US7910570B2 (pl)
EP (2) EP1589976B1 (pl)
JP (2) JP4658918B2 (pl)
KR (1) KR101075929B1 (pl)
CN (1) CN100393360C (pl)
AR (1) AR043013A1 (pl)
AT (1) ATE374612T1 (pl)
AU (1) AU2004210184B2 (pl)
BR (1) BRPI0407039A (pl)
CA (1) CA2513910C (pl)
CO (1) CO5580789A2 (pl)
CY (1) CY1107816T1 (pl)
DE (1) DE602004009288T2 (pl)
DK (1) DK1589976T3 (pl)
ES (1) ES2293215T3 (pl)
GB (1) GB0302572D0 (pl)
IL (1) IL169583A0 (pl)
IS (1) IS2547B (pl)
MX (1) MXPA05008347A (pl)
MY (1) MY140723A (pl)
NO (1) NO20053626L (pl)
NZ (1) NZ541222A (pl)
PL (1) PL214680B1 (pl)
PT (1) PT1589976E (pl)
RU (2) RU2360681C2 (pl)
TW (1) TWI354556B (pl)
UA (1) UA80741C2 (pl)
WO (1) WO2004069260A1 (pl)
ZA (1) ZA200506221B (pl)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0302572D0 (en) * 2003-02-05 2003-03-12 Astrazeneca Ab Method of treatment
MX2007003870A (es) * 2004-10-04 2007-10-02 Wayne State Unviersity Uso de inhibidores de aromatasa para adelgazamiento endometrial en preparacion para procedimientos quirurgicos en la cavidad endometrial y utero.
WO2009075838A2 (en) * 2007-12-10 2009-06-18 Meditrina Pharmaceuticals, Inc. Treatment of menorrhagia with aromatase inhibitor
DE102010003494A1 (de) * 2010-03-31 2011-10-06 Bayer Schering Pharma Aktiengesellschaft Parenterales Abgabesystem, das Aromatasehemmer und Gestagene freisetzt, für die Behandlung von Endometriose
EP2476409A1 (en) * 2011-01-14 2012-07-18 Université Catholique De Louvain Implant comprising a core and a tube encasing the core
RU2541089C1 (ru) * 2013-11-22 2015-02-10 Федеральное государственное бюджетное учреждение "Научно-исследовательски институт акушерства и гинекологии им. Д.О. Отта" Северо-Западного отделения Российской академии медицинских наук Способ комплексного лечения наружного генитального эндометриоза
GB201614179D0 (en) * 2016-08-19 2016-10-05 Mereo Biopharma 2 Ltd Dosage regimen for the treatment of endometriosis
CN109248166A (zh) * 2017-07-13 2019-01-22 国家卫生计生委科学技术研究所 阿那曲唑储库型阴道环的制备及应用
KR102930460B1 (ko) 2022-11-22 2026-04-08 성균관대학교산학협력단 디프레닐로로볼을 유효성분으로 포함하는 자궁내막증 예방 또는 치료용 약제학적 조성물
US20240315958A1 (en) * 2023-03-23 2024-09-26 Chemo Research, S.L. Method and device for providing effective contraception
WO2024197239A1 (en) * 2023-03-23 2024-09-26 William Bologna Bioadhesive compositions and a method of treating endometriosis with aromatase inhibitors without increased gonadatroprin production

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8813353D0 (en) * 1988-06-06 1988-07-13 Ici Plc Therapeutic product
EP0462189B1 (en) * 1989-03-10 1995-09-27 Endorecherche Inc. Combination therapy for treatment of estrogen sensitive diseases
JP2602456B2 (ja) 1990-04-12 1997-04-23 雪印乳業株式会社 子宮内膜症治療剤
DE4344462C2 (de) 1993-12-22 1996-02-01 Schering Ag Zusammensetzung für die Empfängnisverhütung
US5681817A (en) 1994-02-04 1997-10-28 The Medical College Of Hampton Roads Treatment of ovarian estrogen dependent conditions
KR20060098399A (ko) 1998-06-11 2006-09-18 앙도르쉐르슈 인코포레이티드 안드로스트-5-엔-3β,17β-디올을 포함하는 약학 조성물 및그 용도
US6265393B1 (en) * 1998-08-07 2001-07-24 Heinrichs William Leroy Prevention of endometriosis signs or symptons
CA2462081A1 (en) 2000-10-11 2002-04-18 Laura Kragie Composition and method of alleviating adverse side effects and/or enhancing efficacy of agents that inhibit aromatase
CA2434611A1 (en) 2001-01-26 2002-09-19 Pharmacia Italia Spa Combined method for treating hormono-dependent disorders
AU2002240949A1 (en) * 2001-03-21 2002-10-03 Schering Aktiengesellschaft Pharmaceutical combined preparations containing aromatase inhibitors and substances having an estrogen effect in addition to the use thereof for producing a medicament for estrogen-replacement-therapy
GB0120147D0 (en) 2001-08-17 2001-10-10 Metris Therapeutics Ltd Treatment method
WO2003017973A1 (en) 2001-08-31 2003-03-06 Pantarhei Bioscience B.V. A method of treating benign gynaecological disorders and a drug delivery vehicle for use in such a method
IL161630A0 (en) 2001-11-06 2004-09-27 Applied Research Systems Methods of treating endometreosis
KR20040073572A (ko) 2002-01-22 2004-08-19 악조 노벨 엔.브이. 내인성 에스트로겐의 합성을 예방하는 약물의 투여와관련된 호소 증상의 치료에서의 티볼론
AU2003213956A1 (en) * 2002-04-03 2003-10-13 Jencap Research Ltd. Improved hormone replacement therapy
EP1492515A1 (en) 2002-04-03 2005-01-05 Jencap Research Ltd. Pharmaceutical composition comprising an aromatase inhibitor and an estrogen suitable for hormone replacement therapy for a male
AU2003213958A1 (en) * 2002-04-03 2003-10-13 Jencap Research Ltd. Female birth control method
WO2004003147A2 (en) * 2002-06-27 2004-01-08 Centocor, Inc. Cngh0004 polypeptides, antibodies, compositions, methods and uses
GB0302572D0 (en) * 2003-02-05 2003-03-12 Astrazeneca Ab Method of treatment

Also Published As

Publication number Publication date
US7910570B2 (en) 2011-03-22
KR101075929B1 (ko) 2011-10-26
DE602004009288T2 (de) 2008-07-10
WO2004069260A1 (en) 2004-08-19
AU2004210184A1 (en) 2004-08-19
NO20053626L (no) 2005-08-26
ZA200506221B (en) 2006-05-31
NZ541222A (en) 2008-12-24
RU2005127667A (ru) 2006-03-27
CN1747736A (zh) 2006-03-15
RU2008138166A (ru) 2010-03-27
UA80741C2 (en) 2007-10-25
AR043013A1 (es) 2005-07-13
EP1589976A1 (en) 2005-11-02
IS8008A (is) 2005-08-30
TWI354556B (en) 2011-12-21
US20110009373A1 (en) 2011-01-13
GB0302572D0 (en) 2003-03-12
BRPI0407039A (pt) 2006-01-17
PT1589976E (pt) 2007-11-22
CY1107816T1 (el) 2013-06-19
JP4658918B2 (ja) 2011-03-23
AU2004210184B2 (en) 2007-01-04
EP1589976B1 (en) 2007-10-03
CN100393360C (zh) 2008-06-11
ES2293215T3 (es) 2008-03-16
CA2513910C (en) 2012-04-03
JP2011001388A (ja) 2011-01-06
DK1589976T3 (da) 2007-12-27
EP1857111A3 (en) 2009-03-04
MY140723A (en) 2010-01-15
RU2360681C2 (ru) 2009-07-10
MXPA05008347A (es) 2005-11-04
JP2006516602A (ja) 2006-07-06
EP1857111A2 (en) 2007-11-21
US20060142256A1 (en) 2006-06-29
ATE374612T1 (de) 2007-10-15
HK1082918A1 (en) 2006-06-23
KR20050098296A (ko) 2005-10-11
DE602004009288D1 (de) 2007-11-15
IL169583A0 (en) 2007-07-04
CO5580789A2 (es) 2005-11-30
TW200503731A (en) 2005-02-01
PL214680B1 (pl) 2013-09-30
CA2513910A1 (en) 2004-08-19
IS2547B (is) 2009-10-15

Similar Documents

Publication Publication Date Title
IL175858A0 (en) Extended use combination comprising estrogens and progestins
IL179757A0 (en) Novel fluoroglycoside derivatives of pyrazoles, medicaments containing these compounds, and the use thereof
SI1660009T1 (sl) Metode za zdravljenje endometrioze
AP2004003192A0 (en) Combination of azelastine and steroids.
AU4589701A (en) Aryl substituted pyrazoles, triazoles and tetrazoles, and the use thereof
IL182047A0 (en) Indazoles, benzisoxazoles and benzisothiazoles and their use as estrogenic agents
IL169583A0 (en) Composition comprising a combination of an aromatase inhibitor, a progestin and an oestrogen and its use for the treatment of endometriosis
EP1610798A4 (en) ESTRADIOL METABOLITES FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION
IL173182A0 (en) Aryl-condensed 3-arylpyridine compounds and use thereof for controlling pathogenic fungi
GB0207411D0 (en) Azole compounds and their therapeutic use
IL164050A0 (en) fungicidal mixtures based on benzamidoxime derivatives and azoles
SI1589976T1 (sl) Uporaba kombinacije aromataznega inhibitorja, progestina in estrogena za zdravljenje endometrioze
DE602004018921D1 (de) D dienogest
EE200300505A (et) Aromataasi inhibiitori kasutamine ravimi valmistamiseks viljatuse raviks
AP2006003563A0 (en) Fungicidal mixtures for the control of rice pathogens.
ZA200500507B (en) Fungicidal mixtures based on benzamidoxime derivatives, benzophenones and on an azole
EG23743A (en) Fungicidal mixtures based on triazolpyrimidines and azoles
IL173855A0 (en) Fungicidal mixtures for fighting against rice pathogens
GB0400659D0 (en) Microprocessor, related method of operating the same and related instruction word
IL175050A0 (en) Fungicidal mixtures for the prevention of rice pathogens
IL173608A0 (en) 15-d-homosteroids having an androgenic effect
IL169094A0 (en) 1-n-phenylamino-1h-imidazole derivatives as aromatase inhibitors
HK1102333A (en) Therapeutic, prophylactic and diagnostic agents for hepatitis b
AU2003214382A8 (en) Orthopaedic brace
GB0328826D0 (en) Body wrap